Table 2.
Study characteristics for SVF studies, n = 7.
| Authors | Type of Study | Treatment vs. Control | No. of Patients in Control Group (Gender) | No. of Patients in Treatment Group (Gender) | Age, Mean | Location of Defect | Grade of OA (Grading Classification) |
|---|---|---|---|---|---|---|---|
| Garza et al. (2020) [69] | Prospective double blinded RCT | High dose SVF vs low dose SVF vs placebo | 13 (6M, 7F) | 13 (4M, 9F) for low dose SVF. 13 (7M, 6F) for high dose SVF. |
59.0 | Knee | II–III (K-L) |
| Hong et al. (2019) [70] | Prospective RCT | One knee with SVF and the other with hyaluronic acid placebo | 16 (3M, 13F) | 16 (3M, 13F) | Not specified | Knee | II-III (K-L) |
| Tran et al. (2019) [78] | Prospective non-randomised trial | Arthroscopic microfracture vs arthroscopic microfracture and injection of SVF | 15 (3M, 12F) | 18 (5M, 13F) | 58.64 | Knee | II–III (K-L) |
| Yokota et al. (2017) [68] | Prospective uncontrolled | Injection of SVF, no control | N/A | 13 (2M, 11F) | 74.5 | Knee | III–IV (K-L) |
| Nguyen et al. (2016) [67] | Prospective unblinded, non-randomised trial | Arthroscopic fracture vs arthroscopic fracture and injection of SVF and PRP. | 15 (3M, 12F) | 15 (3M, 12F) | 58.4 | Knee | II–III (K-L) |
| Koh et al. (2013) [66] | Prospective cohort study | SVF at 1 dose with PRP, no control | N/A | 18 (6M, 12F) | 54.6 | Knee | III–IV (K-L) |
| Panni et al. (2019) [74] | Retrospective single arm study | SVF at 1 dose following arthroscopy (for chondral shaving/abrasion and/or meniscal regularization), no control | N/A | 52 (22M, 30F) | 57.3 | Knee | 0–II (K-L) |
BS = Brandt Radiographic Grading Scale for Osteoarthritis, F = Female, K-L = Kellgren-Lawrence, M= Male, N/A = Not Applicable, OA = Osteoarthritis, RCT = Randomised Controlled Trial, SVF = Stromal Vascular Fraction.